EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Re-discussions in the decision process of the Italian Medicine Agency: a quantitative assessment of causes and implications

Michele Caimmi iD, Beatrice Canali iD, Anita Ciarlo iD, Gloria Lombardi, Chiara Vassallo iD, Laura Candelora iD

Global and Regional Health Technology Assessment · 22.04.2026 · 13 (1) · 87-94

DOI: 10.33393/grhta.2026.3717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 22.04.2026. Verfasst von Michele Caimmi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Real World Solutions, IQVIA Solutions S.r.l., Milano - Italy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Until 2024, Pricing and Reimbursement (P&R) requests for medicinal products in Italy were assessedby two separate bodies within AIFA: at first by the Technical Scientific Committee (CTS), then by the Pricingand Reimbursement Committee (CPR), occasionally requiring CTS re-discussion after CPR review, potentially extending the time to reimbursement (TTR). In March 2024, the Scientific and Economic Commission (CSE) replacedCTS and CPR. This study investigates the impact of CTS re-discussions on TTR, identifying common features andnegotiation outcomes.

Methods

We analyzed P&R procedures completed from 2016 through a proprietary IQVIA database trackingtherapies approved by the European Commission. Re-discussions were defined as procedures evaluated by CTSafter CPR review. Analyses included univariate statistics to evaluate average TTR differences, logistic regressionsto identify factors associated with re-discussion, and Fisher’s exact tests to examine re-discussion rates by negotiation outcomes.

Results

Among 474 requests, 14.98% were re-discussed. Re-discussion was associated with a significantly longerTTR (+50.41%; p

Schlagwörter

Stichwörter der Autor:innen

AIFACPRCSECTSNegotiation outcomesRe-discussionTime to reimbursement

Autor:innen und Institutionen

  • Real World Solutions, IQVIA Solutions S.r.l., Milano - Italy.

ORCID-Profile: Michele Caimmi, Beatrice Canali, Anita Ciarlo, Chiara Vassallo, Laura Candelora

Zitieren

APA

Caimmi, M., Canali, B., Ciarlo, A., Lombardi, G., Vassallo, C., & Candelora, L. (2026). Re-discussions in the decision process of the Italian Medicine Agency: a quantitative assessment of causes and implications. Global and Regional Health Technology Assessment, 13(1), 87-94. https://doi.org/10.33393/grhta.2026.3717

Vancouver

Caimmi M, Canali B, Ciarlo A, Lombardi G, Vassallo C, Candelora L. Re-discussions in the decision process of the Italian Medicine Agency: a quantitative assessment of causes and implications. Global and Regional Health Technology Assessment. 2026;13(1):87-94. doi:10.33393/grhta.2026.3717

BibTeX
@article{Caimmi2026,
  author = {Caimmi, Michele and Canali, Beatrice and Ciarlo, Anita and Lombardi, Gloria and Vassallo, Chiara and Candelora, Laura},
  title = {Re-discussions in the decision process of the Italian Medicine Agency: a quantitative assessment of causes and implications},
  journal = {Global and Regional Health Technology Assessment},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {87--94},
  doi = {10.33393/grhta.2026.3717}
}
Kostenlos starten →